Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Consensus PT from Analysts
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued […]
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have been given a consensus recommendation of “Buy” by the six research firms that are presently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued […]
